Fig. 9

Expressions of downstream molecules of GPR120- and NF-κB-signaling pathway in rat urinary bladders following cyclophosphamide (CYP) stimulation with and without GPR120 agonist / extracorporeal shock wave treatment (ESWT). a-d Protein expressions of pro-inflammatory (i.e., TAK1, NF-κB) and anti-inflammatory (i.e., GPR120) markers. e-j Protein expressions of IL-1β, IL-6, MCP-1, TNF-α, and iNOS (i.e., downstream molecules of NF-κB mediated-inflammatory signaling pathway) in CYP-treated rat bladder with and without GPR120 agonist / extracorporeal shock wave treatment (ESWT) (n = 6 per group). Values expressed as the mean ± SEM. *p < 0.05, **p < 0.01 vs. CYP; ^†p < 0.05, ^††p < 0.01 vs. controls; Significance of differences determined by one-way ANOVA followed by Bonferroni’s post-hoc comparisons tests. SC = sham control; CYP = cyclophosphamide; ESWT = extracorporeal shock wave treatment; GW9508 = GPR120 agonist